VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q88452352 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000308.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q88452352‏
024 ‎‡a 0000-0001-6693-9860‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q88452352‏
100 0 ‎‡a মার্ক ওয়ারেন‏ ‎‡9 bn‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Mark Warren‏ ‎‡c researcher (ORCID 0000-0001-6693-9860)‏ ‎‡9 en‏
400 0 ‎‡a Mark Warren‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials.‏
670 ‎‡a Author's Semaglutide improves health-related quality of life vs placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)‏
670 ‎‡a Author's Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials‏
909 ‎‡a (orcid) 0000000166939860‏ ‎‡9 1‏
919 ‎‡a semaglutideinducesweightlossinsubjectswithtype2diabetesregardlessofbaselinebmiorgastrointestinaladverseeventsinthesustain1to5trials‏ ‎‡A Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials‏ ‎‡9 1‏
919 ‎‡a semaglutideimproveshealthrelatedqualityoflifevsplacebowhenaddedtostandardofcareinpatientswithtype2diabetesathighcardiovascularrisksustain6‏ ‎‡A Semaglutide improves health-related quality of life vs placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)‏ ‎‡9 1‏
919 ‎‡a semaglutideasatherapeuticoptionforelderlypatientswithtype2diabetespooledanalysisofthesustain15trials‏ ‎‡A Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials.‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 CAOONL|ncf10114044
996 ‎‡2 BNF|12163596
996 ‎‡2 ISNI|0000000053450452
996 ‎‡2 LC|no2007015408
996 ‎‡2 BNC|981061020266606706
996 ‎‡2 LC|nb2012007094
996 ‎‡2 LC|nr 93012010
996 ‎‡2 RERO|A003958832
996 ‎‡2 LNB|LNC10-000035115
996 ‎‡2 CAOONL|ncf10616696
996 ‎‡2 PLWABN|9810631228605606
996 ‎‡2 NII|DA02683378
996 ‎‡2 LC|n 88010760
996 ‎‡2 LC|no2023104124
996 ‎‡2 DNB|1253224447
996 ‎‡2 ISNI|0000000042369341
996 ‎‡2 DNB|1287948820
996 ‎‡2 NKC|uk2013789987
996 ‎‡2 J9U|987007281171805171
996 ‎‡2 LC|n 86045306
996 ‎‡2 NUKAT|n 01717795
996 ‎‡2 LC|no2007016046
996 ‎‡2 SUDOC|151319049
996 ‎‡2 LC|n 2012002906
996 ‎‡2 DNB|1175161071
996 ‎‡2 NKC|xx0079991
996 ‎‡2 DBC|87097969743919
996 ‎‡2 ISNI|0000000042476753
996 ‎‡2 NKC|mub20221156628
996 ‎‡2 J9U|987007421908305171
996 ‎‡2 J9U|987007452170905171
996 ‎‡2 NII|DA13050373
996 ‎‡2 LC|no2021077280
996 ‎‡2 BNE|XX963617
996 ‎‡2 J9U|987007379107305171
996 ‎‡2 NTA|428227295
996 ‎‡2 J9U|987007330134105171
996 ‎‡2 ISNI|0000000110074335
996 ‎‡2 ISNI|0000000361179182
996 ‎‡2 LC|no2013118185
996 ‎‡2 LC|n 00096839
996 ‎‡2 NTA|353990191
996 ‎‡2 BIBSYS|49392
996 ‎‡2 NUKAT|n 2016126370
996 ‎‡2 ISNI|0000000067825227
996 ‎‡2 NUKAT|n 2011200646
996 ‎‡2 LC|no2006013043
996 ‎‡2 LC|n 95071047
996 ‎‡2 ISNI|0000000078271282
996 ‎‡2 DNB|124677908
996 ‎‡2 ISNI|0000000114507767
996 ‎‡2 CAOONL|ncf12095123
996 ‎‡2 DNB|1235010155
996 ‎‡2 LC|n 85092546
996 ‎‡2 BNE|XX4906470
996 ‎‡2 BIBSYS|11069565
996 ‎‡2 LC|no2014128867
996 ‎‡2 NTA|345503341
996 ‎‡2 SUDOC|132284391
996 ‎‡2 ISNI|0000000401469521
996 ‎‡2 ISNI|0000000083727694
996 ‎‡2 PLWABN|9812405933005606
996 ‎‡2 ISNI|000000036772521X
996 ‎‡2 CAOONL|ncf11340796
996 ‎‡2 BNF|15747186
996 ‎‡2 LC|n 86039655
996 ‎‡2 LC|nb2009017066
996 ‎‡2 NUKAT|n 2013055574
996 ‎‡2 LC|n 92120100
996 ‎‡2 DNB|143374052
996 ‎‡2 SUDOC|068261136
996 ‎‡2 LC|no 99021082
996 ‎‡2 LC|n 93085342
996 ‎‡2 ISNI|0000000075574747
996 ‎‡2 BNE|XX5665458
996 ‎‡2 ISNI|0000000084797846
996 ‎‡2 ISNI|0000000067445443
996 ‎‡2 NSK|000587030
996 ‎‡2 BIBSYS|5078287
996 ‎‡2 NTA|074283138
996 ‎‡2 BNF|14544126
996 ‎‡2 SUDOC|185087922
996 ‎‡2 LC|no2010161678
996 ‎‡2 SUDOC|03016379X
996 ‎‡2 NII|DA13424484
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏